Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $99.8 million.

  • Arcutis Biotherapeutics' Total Current Liabilities fell 4213.75% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year decrease of 4213.75%. This contributed to the annual value of $81.0 million for FY2024, which is 7359.43% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Total Current Liabilities of $99.8 million as of Q3 2025, which was down 4213.75% from $103.9 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Total Current Liabilities ranged from a high of $172.4 million in Q3 2024 and a low of $13.3 million during Q2 2021
  • In the last 5 years, Arcutis Biotherapeutics' Total Current Liabilities had a median value of $37.8 million in 2022 and averaged $54.0 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Total Current Liabilities soared by 31162.6% in 2024, and later crashed by 4213.75% in 2025.
  • Arcutis Biotherapeutics' Total Current Liabilities (Quarter) stood at $33.3 million in 2021, then rose by 13.45% to $37.8 million in 2022, then grew by 23.44% to $46.7 million in 2023, then soared by 73.59% to $81.0 million in 2024, then grew by 23.15% to $99.8 million in 2025.
  • Its Total Current Liabilities stands at $99.8 million for Q3 2025, versus $103.9 million for Q2 2025 and $91.1 million for Q1 2025.